Late side-effects after curative intent radiotherapy: Identification of hypersensitive patients for personalized strategy

Critical Reviews in Oncology/Hematology

Volumn 93, Issue 3, 2015, Pages 312-319

  Bourgier, Céline ^a,b,c   Lacombe, Jérôme ^a,b   Solassol, JérÔme ^a,b,d   Mange, Alain ^a,b   Pèlegrin, André ^a,b   Ozsahin, Mahmut ^e   Azria, David ^a,b,c  

^a UNIV MONTPELLIER   (France)

^b INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

^c CENTRE VAL D AURELLE   (France)

^d HÔPITAL ARNAUD DE VILLENEUVE   (France)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Predictive markers; Radiotherapy outcome

Indexed keywords

BIOLOGICAL MARKER;

BREAST CANCER; CANCER RADIOTHERAPY; CELL DEATH; DNA REPAIR; FIBROBLAST; FIBROSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOMICS; HUMAN; LUNG FIBROSIS; LYMPHOCYTE; NON SMALL CELL LUNG CANCER; NONHUMAN; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PROSTATE CANCER; PROTEOMICS; QUALITY OF LIFE; RADIATION SICKNESS; RADIOSENSITIVITY; REVIEW; RISK FACTOR; ADVERSE EFFECTS; COMPLICATION; MORTALITY; NEOPLASMS; PROGNOSIS; RADIATION DOSE; RADIATION INJURIES; SURVIVOR; TIME; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; INDIVIDUALIZED MEDICINE; NEOPLASMS; PROGNOSIS; RADIATION INJURIES; RADIATION TOLERANCE; RADIOTHERAPY; RISK FACTORS; SURVIVORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84922449020     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2014.11.004     Document Type: Review

References (50)

1. Pepe M.S., Etzioni R., Feng Z., et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001, 93:1054-1061.
2. Azria D., Betz M., Bourgier C., et al. Identifying patients at risk for late radiation-induced toxicity. Crit Rev Oncol Hematol 2012, 84(Suppl. 1):e35-e41.
3. Fertil B., Malaise E.P. Inherent cellular radiosensitivity as a basic concept for human tumor radiotherapy. Int J Radiat Oncol Biol Phys 1981, 7:621-629.
4. Malaise E.P., Fertil B., Deschavanne P.J., et al. Initial slope of radiation survival curves is characteristic of the origin of primary and established cultures of human tumor cells and fibroblasts. Radiat Res 1987, 111:319-333.
5. Begg A.C., Russell N.S., Knaken H., et al. Lack of correlation of human fibroblast radiosensitivity in vitro with early skin reactions in patients undergoing radiotherapy. Int J Radiat Biol 1993, 64:393-405.
6. West C.M., Barnett G.C. Genetics and genomics of radiotherapy toxicity: towards prediction. Genome Med 2011, 3:52.
7. Dickson J., Magee B., Stewart A., et al. Relationship between residual radiation-induced DNA double-strand breaks in cultured fibroblasts and late radiation reactions: a comparison of training and validation cohorts of breast cancer patients. Radiother Oncol 2002, 62:321-326.
8. Kiltie A.E., Ryan A.J., Swindell R., et al. A correlation between residual radiation-induced DNA double-strand breaks in cultured fibroblasts and late radiotherapy reactions in breast cancer patients. Radiother Oncol 1999, 51:55-65.
9. Abbaszadeh F., Clingen P.H., Arlett C.F., et al. A novel splice variant of the DNA-PKcs gene is associated with clinical and cellular radiosensitivity in a patient with xeroderma pigmentosum. J Med Genet 2010, 47:176-181.
10. Chua M.L., Somaiah N., A'Hern R., et al. Residual DNA and chromosomal damage in ex vivo irradiated blood lymphocytes correlated with late normal tissue response to breast radiotherapy. Radiother Oncol 2011, 99:362-366.
11. Perera F., Chisela F., Stitt L., et al. TLD skin dose measurements and acute and late effects after lumpectomy and high-dose-rate brachytherapy only for early breast cancer. Int J Radiat Oncol Biol Phys 2005, 62:1283-1290.
12. Burnet N.G., Nyman J., Turesson I., et al. Prediction of normal-tissue tolerance to radiotherapy from in-vitro cellular radiation sensitivity. Lancet 1992, 339:1570-1571.
13. Geara F.B., Peters L.J., Ang K.K., et al. Prospective comparison of in vitro normal cell radiosensitivity and normal tissue reactions in radiotherapy patients. Int J Radiat Oncol Biol Phys 1993, 27:1173-1179.
14. Johansen J., Bentzen S.M., Overgaard J., et al. Evidence for a positive correlation between in vitro radiosensitivity of normal human skin fibroblasts and the occurrence of subcutaneous fibrosis after radiotherapy. Int J Radiat Biol 1994, 66:407-412.
15. West C.M., Elyan S.A., Berry P., et al. A comparison of the radiosensitivity of lymphocytes from normal donors, cancer patients, individuals with ataxia-telangiectasia (A-T) and A-T heterozygotes. Int J Radiat Biol 1995, 68:197-203.
16. Floyd D.N., Cassoni A.M. Intrinsic radiosensitivity of adult and cord blood lymphocytes as determined by the micronucleus assay. Eur J Cancer 1994, 30A:615-620.
17. Jones L.A., Scott D., Cowan R., et al. Abnormal radiosensitivity of lymphocytes from breast cancer patients with excessive normal tissue damage after radiotherapy: chromosome aberrations after low dose-rate irradiation. Int J Radiat Biol 1995, 67:519-528.
18. Ozsahin M., Ozsahin H., Shi Y., et al. Rapid assay of intrinsic radiosensitivity based on apoptosis in human CD4 and CD8 T-lymphocytes. Int J Radiat Oncol Biol Phys 1997, 38:429-440.
19. Zamai L., Falcieri E., Zauli G., et al. Optimal detection of apoptosis by flow cytometry depends on cell morphology. Cytometry 1993, 14:891-897.
20. Crompton N.E., Miralbell R., Rutz H.P., et al. Altered apoptotic profiles in irradiated patients with increased toxicity. Int J Radiat Oncol Biol Phys 1999, 45:707-714.
21. Crompton N.E., Shi Y.Q., Emery G.C., et al. Sources of variation in patient response to radiation treatment. Int J Radiat Oncol Biol Phys 2001, 49:547-554.
22. Ozsahin M., Crompton N.E., Gourgou S., et al. CD4 and CD8 T-lymphocyte apoptosis can predict radiation-induced late toxicity: a prospective study in 399 patients. Clin Cancer Res 2005, 11:7426-7433.
23. Bordon E., Henriquez Hernandez L.A., Lara P.C., et al. Prediction of clinical toxicity in localized cervical carcinoma by radio-induced apoptosis study in peripheral blood lymphocytes (PBLs). Radiat Oncol 2009, 4:58.
24. Schnarr K., Boreham D., Sathya J., et al. Radiation-induced lymphocyte apoptosis to predict radiation therapy late toxicity in prostate cancer patients. Int J Radiat Oncol Biol Phys 2009, 74:1424-1430.
25. Azria D., Belkacemi Y., Romieu G., et al. Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial. Lancet Oncol 2010, 11:258-265.
26. Azria D. Multicentric and prospective evaluation of predictive assay for late radio-induced toxicities through radio-induced CD8-lymphocytes apoptosis assay in breast and prostate cancers 2005, National Grant.
27. Alsner J., Andreassen C.N., Overgaard J. Genetic markers for prediction of normal tissue toxicity after radiotherapy. Semin Radiat Oncol 2008, 18:126-135.
28. Andreassen C.N. Searching for genetic determinants of normal tissue radiosensitivity - are we on the right track?. Radiother Oncol 2010, 97:1-8.
29. Barnett G.C., West C.M., Dunning A.M., et al. Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nat Rev Cancer 2009, 9:134-142.
30. Andreassen C.N., Dikomey E., Parliament M., et al. Will SNPs be useful predictors of normal tissue radiosensitivity in the future?. Radiother Oncol 2012, 105:283-288.
31. Barnett G.C., Elliott R.M., Alsner J., et al. Individual patient data meta-analysis shows no association between the SNP rs1800469 in TGFB and late radiotherapy toxicity. Radiother Oncol 2012, 105:289-295.
32. Barnett G.C., Coles C.E., Elliott R.M., et al. Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. Lancet Oncol 2012, 13:65-77.
33. Kerns S.L., Ostrer H., Stock R., et al. Genome-wide association study to identify single nucleotide polymorphisms (SNPs) associated with the development of erectile dysfunction in African-American men after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010, 78:1292-1300.
34. Michikawa Y., Suga T., Ishikawa A., et al. Genome wide screen identifies microsatellite markers associated with acute adverse effects following radiotherapy in cancer patients. BMC Med Genet 2010, 11:123.
35. Anscher M.S., Murase T., Prescott D.M., et al. Changes in plasma TGF beta levels during pulmonary radiotherapy as a predictor of the risk of developing radiation pneumonitis. Int J Radiat Oncol Biol Phys 1994, 30:671-676.
36. Anscher M.S., Kong F.M., Marks L.B., et al. Changes in plasma transforming growth factor beta during radiotherapy and the risk of symptomatic radiation-induced pneumonitis. Int J Radiat Oncol Biol Phys 1997, 37:253-258.
37. Li C., Wilson P.B., Levine E., et al. TGF-beta1 levels in pre-treatment plasma identify breast cancer patients at risk of developing post-radiotherapy fibrosis. Int J Cancer 1999, 84:155-159.
38. Novakova-Jiresova A., Van Gameren M.M., Coppes R.P., et al. Transforming growth factor-beta plasma dynamics and post-irradiation lung injury in lung cancer patients. Radiother Oncol 2004, 71:183-189.
39. De Jaeger K., Seppenwoolde Y., Kampinga H.H., et al. Significance of plasma transforming growth factor-beta levels in radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004, 58:1378-1387.
40. Fleckenstein K., Gauter-Fleckenstein B., Jackson I.L., et al. Using biological markers to predict risk of radiation injury. Semin Radiat Oncol 2007, 17:89-98.
41. Stenmark M.H., Cai X.W., Shedden K., et al. Combining physical and biologic parameters to predict radiation-induced lung toxicity in patients with non-small-cell lung cancer treated with definitive radiation therapy. Int J Radiat Oncol Biol Phys 2012, 84:e217-e222.
42. Lacombe J., Azria D., Mange A., et al. Proteomic approaches to identify biomarkers predictive of radiotherapy outcomes. Expert Rev Proteomics 2013, 10:33-42.
43. Marchetti F., Coleman M.A., Jones I.M., et al. Candidate protein biodosimeters of human exposure to ionizing radiation. Int J Radiat Biol 2006, 82:605-639.
44. Guipaud O., Holler V., Buard V., et al. Time-course analysis of mouse serum proteome changes following exposure of the skin to ionizing radiation. Proteomics 2007, 7:3992-4002.
45. Ao X., Lubman D.M., Davis M.A., et al. Comparative proteomic analysis of radiation-induced changes in mouse lung: fibrosis-sensitive and -resistant strains. Radiat Res 2008, 169:417-425.
46. Cai X.W., Shedden K., Ao X., et al. Plasma proteomic analysis may identify new markers for radiation-induced lung toxicity in patients with non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2010, 77:867-876.
47. Cai X.W., Shedden K.A., Yuan S.H., et al. Baseline plasma proteomic analysis to identify biomarkers that predict radiation-induced lung toxicity in patients receiving radiation for non-small cell lung cancer. J Thorac Oncol 2011, 6:1073-1078.
48. Torres-Roca J.F. A molecular assay of tumor radiosensitivity: a roadmap towards biology-based personalized radiation therapy. Per Med 2012, 9:547-557.
49. Bourgier C., Levy A., Vozenin M.C., et al. Pharmacological strategies to spare normal tissues from radiation damage: useless or overlooked therapeutics?. Cancer Metastasis Rev 2012, 31:699-712.
50. Bourgier C., Monceau V., Bourhis J. Pharmacological modulation of late radio-induced side effects. Cancer Radiother 2011, 15:383-389.